Literature DB >> 21264545

Hyponatremia associated with Ipilimumab-induced hypophysitis.

Zachary R Barnard1, Brian P Walcott, Kristopher T Kahle, Brian V Nahed, Jean Valery Coumans.   

Abstract

A 75-year-old woman with a history of stage IV metastatic melanoma underwent treatment with the CTLA-4 blocking agent Ipilimumab. She presented 2 months after initiating treatment with a severe headache. Laboratories were consistent with severe hyponatremia. MRI of the brain revealed enlargement of the pituitary gland, enhancement of the infundibulum, and an enhancing, centrally necrotic foci in the anterior pituitary. Based on the clinical and radiographic findings, she was diagnosed with treatment-related syndrome of inappropriate antidiuretic hormone secretion (SIADH). Effective treatment consisted of fluid restriction, hyperosmolar therapy, and steroids.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21264545     DOI: 10.1007/s12032-010-9794-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  19 in total

Review 1.  Clinical practice. The syndrome of inappropriate antidiuresis.

Authors:  David H Ellison; Tomas Berl
Journal:  N Engl J Med       Date:  2007-05-17       Impact factor: 91.245

2.  Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management.

Authors:  Ewout J Hoorn; Jan Lindemans; Robert Zietse
Journal:  Nephrol Dial Transplant       Date:  2005-09-02       Impact factor: 5.992

3.  Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.

Authors:  Ajay V Maker; Giao Q Phan; Peter Attia; James C Yang; Richard M Sherry; Suzanne L Topalian; Udai S Kammula; Richard E Royal; Leah R Haworth; Catherine Levy; David Kleiner; Sharon A Mavroukakis; Michael Yellin; Steven A Rosenberg
Journal:  Ann Surg Oncol       Date:  2005-10-21       Impact factor: 5.344

4.  Neurological manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes.

Authors:  A I Arieff; F Llach; S G Massry
Journal:  Medicine (Baltimore)       Date:  1976-03       Impact factor: 1.889

Review 5.  Incidence and prevalence of hyponatremia.

Authors:  Ashish Upadhyay; Bertrand L Jaber; Nicolaos E Madias
Journal:  Am J Med       Date:  2006-07       Impact factor: 4.965

6.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

7.  Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.

Authors:  James C Yang; Marybeth Hughes; Udai Kammula; Richard Royal; Richard M Sherry; Suzanne L Topalian; Kimberly B Suri; Catherine Levy; Tamika Allen; Sharon Mavroukakis; Israel Lowy; Donald E White; Steven A Rosenberg
Journal:  J Immunother       Date:  2007 Nov-Dec       Impact factor: 4.456

Review 8.  The syndrome of inappropriate antidiuretic hormone: current and future management options.

Authors:  Mark Sherlock; Chris J Thompson
Journal:  Eur J Endocrinol       Date:  2010-02-17       Impact factor: 6.664

9.  Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

Authors:  Bradley C Carthon; Jedd D Wolchok; Jianda Yuan; Ashish Kamat; Derek S Ng Tang; Jingjing Sun; Geoffrey Ku; Patricia Troncoso; Christopher J Logothetis; James P Allison; Padmanee Sharma
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531

Review 10.  Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy.

Authors:  Juan-Andres Rivera
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

View more
  16 in total

Review 1.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

2.  Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.

Authors:  Joke Marlier; Veronique Cocquyt; Lieve Brochez; Simon Van Belle; Vibeke Kruse
Journal:  Endocrine       Date:  2014-02-21       Impact factor: 3.633

Review 3.  Ipilimumab and its toxicities: a multidisciplinary approach.

Authors:  Leslie A Fecher; Sanjiv S Agarwala; F Stephen Hodi; Jeffrey S Weber
Journal:  Oncologist       Date:  2013-06-17

Review 4.  Pituitary side effects of old and new drugs.

Authors:  Maria Chiara Zatelli; Maria Rosaria Ambrosio; Marta Bondanelli; Ettore Degli Uberti
Journal:  J Endocrinol Invest       Date:  2014-07-29       Impact factor: 4.256

Review 5.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

Review 6.  Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies.

Authors:  Annu Susan George; Cornelius J Fernandez; Dilip Eapen; Joseph M Pappachan
Journal:  touchREV Endocrinol       Date:  2021-04-28

7.  The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma.

Authors:  Claire Verschraegen
Journal:  Cancer Manag Res       Date:  2012-01-18       Impact factor: 3.989

Review 8.  The side effects of immune checkpoint inhibitor therapy on the endocrine system.

Authors:  Itivrita Goyal; Manu Raj Pandey; Rajeev Sharma; Ajay Chaudhuri; Paresh Dandona
Journal:  Indian J Med Res       Date:  2021-04       Impact factor: 5.274

Review 9.  Immune checkpoint inhibitor therapy associated hypophysitis.

Authors:  Moeber Mahzari; Dora Liu; Amel Arnaout; Heather Lochnan
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2015-03-25

Review 10.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.

Authors:  Anne Bertrand; Marie Kostine; Thomas Barnetche; Marie-Elise Truchetet; Thierry Schaeverbeke
Journal:  BMC Med       Date:  2015-09-04       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.